Wide Ranks

ABEO

Abeona Therapeutics Inc.

6.41

Top Statistics
Market Cap 278 M Forward PE -5.70 Revenue Growth 0.00 %
Current Ratio 7.47 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.89 Enterprise / Revenue Price To Sales Trailing12 Months Infinity
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 122 M Total Cash Per Share 2.83 Total Debt 23 M
Total Debt To Equity 31.63 Current Ratio 7.47 Book Value Per Share 0.5590
All Measures
Short Ratio 1079.00 % Message Board Id finmb_360935 Shares Short Prior Month 2 M
Return On Equity -1.27 City Cleveland Uuid 6a7dfae4-c578-3526-bdcd-a5a90d9256dd
Previous Close 6.03 First Trade Date Epoch Utc 338 M Book Value 0.5590
Beta 1.50 Total Debt 23 M Volume 718843
Price To Book 11.47 Last Split Date 1 B Fifty Two Week Low 3.05
Total Cash Per Share 2.83 Shares Short Previous Month Date 1 B Target Median Price 17.50
Max Age 86400 Recommendation Mean 1.20 Sand P52 Week Change 0.3133
Last Dividend Value 3706.25 Target Mean Price 16.75 Net Income To Common -52599000
Short Percent Of Float 0.0629 Implied Shares Outstanding 43 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 382050 Average Volume10days 382050
Total Cash 122 M Next Fiscal Year End 1 B Held Percent Insiders 0.0510
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 6.03 Target Low Price 9.50 Gmt Off Set Milliseconds -18000000
Fifty Day Average 6.24 Open 6.09 Free Cashflow -20499376
State OH Dividend Yield 0.00 % Return On Assets -0.3781
Time Zone Short Name EST Trailing Eps -2.05 Day Low 6.03
Address1 6555 Carnegie Avenue Shares Outstanding 43 M Price Hint 2
Target High Price 21.00 Website https://www.abeonatherapeutics.com 52 Week Change 0.3354
Average Volume 270610 Forward Eps -1.48 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 738.30 % Last Split Factor 1:25
Regular Market Day High 6.54 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 31.63 Fifty Two Week High 9.01 Day High 6.54
Shares Short 2 M Regular Market Open 6.09 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0609
Operating Cashflow -42203000 Currency USD Time Zone Full Name America/New_York
Market Cap 278 M Is_nasdaq_100 False Zip 44103
Quote Type EQUITY Industry Biotechnology Long Name Abeona Therapeutics Inc.
Regular Market Day Low 6.03 Held Percent Institutions 0.7754 Current Price 6.41
Address2 4th Floor Enterprise To Ebitda -2.89 Financial Currency USD
Current Ratio 7.47 Industry Disp Biotechnology Number Of Analyst Opinions 6
Country United States Float Shares 28 M Two Hundred Day Average 5.76
Ir Website http://www.accesspharma.com/investor-relations/ Enterprise Value 158 M Price To Sales Trailing12 Months Infinity
Forward PE -5.70 Regular Market Volume 718843 Last Dividend Date 954 M
Ebitda -54747000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.

Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.

The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.

In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.

The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.

Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.